PCOS and Your Genome: Why the Same Diagnosis Looks Different in Every Woman

Polycystic ovary syndrome affects an estimated 8 to 13% of women of reproductive age globally. It is also one of the most poorly managed conditions in women's health — not because treatment options don't exist, but because PCOS is routinely treated as a single condition when it is, in fact, several distinct phenotypes that share a diagnostic label.

The Rotterdam diagnostic criteria require two of three features: irregular ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. These criteria are broad enough to capture women whose underlying pathophysiology is fundamentally different from one another. A woman with insulin-driven PCOS is not the same patient as one with androgen-excess PCOS or an inflammatory presentation. Treating all three identically — which is what standard-of-care approaches typically do — is why so many women cycle through interventions without sustained improvement.

Your genetics don't cause PCOS unilaterally. But they substantially determine which phenotype you express, and which interventions are likely to work.

Phenotype 1: Androgen excess

CYP11A1 encodes the cholesterol side-chain cleavage enzyme, the rate-limiting step in androgen synthesis in the ovaries and adrenal glands. The (TTTTA)n microsatellite polymorphism in the CYP11A1 promoter region is associated with elevated androgen production independent of LH stimulation. Women carrying these variants often present with more pronounced hirsutism, higher free testosterone, and acne that doesn't respond well to standard dietary intervention alone.

The androgen receptor gene (AR) carries a CAG repeat polymorphism that modulates receptor sensitivity. Shorter CAG repeats confer greater androgen receptor sensitivity — meaning the same circulating testosterone level produces a stronger biological response. A woman with short CAG repeats may experience significant androgenic symptoms at testosterone levels that would be asymptomatic in a woman with longer repeats. Blood tests showing "normal" testosterone in this context are genuinely misleading.

For androgen-excess phenotypes, anti-androgenic interventions are the rational priority. Spearmint tea has genuine 5α-reductase inhibitory activity supported by clinical data. Saw palmetto and reishi mushroom also modulate androgen receptor signalling. DIM (diindolylmethane) from cruciferous vegetables promotes more favourable oestrogen and androgen metabolite ratios. Cycle-synced training that reduces high-intensity volume in the luteal phase can lower adrenal androgen output meaningfully over time.

Phenotype 2: Insulin resistance

INSR encodes the insulin receptor. The rs1799817 variant is associated with reduced insulin receptor signalling efficiency, requiring higher insulin levels to achieve normal glucose uptake. In PCOS, elevated insulin directly stimulates ovarian androgen production through LH receptors in theca cells — this is the primary mechanism by which insulin resistance drives androgen excess in this phenotype.

IRS1 (insulin receptor substrate 1) rs1801278 (Gly972Arg) impairs downstream insulin signalling and is consistently associated with reduced sensitivity to metformin — one of the most commonly prescribed interventions for insulin-resistant PCOS. This variant predicts poor response to the standard pharmaceutical approach, yet it is almost never tested before prescription.

Myo-inositol is among the best-evidenced non-pharmaceutical interventions for insulin-resistant PCOS, acting as both an insulin sensitiser and an FSH signal mediator. Berberine has comparable efficacy to metformin in several trials and does not share the IRS1-related resistance mechanism. For this phenotype, the dietary priority is unambiguously glycaemic control — low glycaemic load eating, time-restricted feeding, and resistance training to improve insulin sensitivity peripherally.

Phenotype 3: Inflammatory

TNF-α is elevated in many women with PCOS independently of BMI or insulin resistance. The TNF rs1800629 G>A variant in the promoter region is associated with higher TNF-α transcription and has been found at higher frequency in PCOS populations in multiple studies. Elevated TNF-α directly impairs insulin signalling, disrupts ovarian follicle maturation, and drives the chronic low-grade inflammation that characterises this phenotype.

IL-6 variants — particularly rs1800795 — influence the inflammatory baseline in ways that affect gonadotropin secretion, insulin sensitivity, and adrenal androgen output simultaneously. Women with the inflammatory phenotype often have disproportionately poor responses to carbohydrate restriction alone while showing significant improvement with anti-inflammatory protocols: omega-3 fatty acids (EPA/DHA at 2-4g daily), curcumin with piperine, and removal of highly processed food and refined seed oils.

FSHR and the ovarian response

The follicle-stimulating hormone receptor (FSHR) Ser680Asn variant influences ovarian sensitivity to FSH. The Ser/Ser genotype is associated with lower FSH receptor sensitivity, meaning higher FSH levels are required to drive follicle development — directly relevant to understanding the accumulation of small antral follicles that fail to reach dominance. For women pursuing ovulation induction or IVF, FSHR genotype predicts stimulation response with reasonable precision and should inform protocol design.

Understanding which phenotype is primary — which your genetics can substantially inform — is the prerequisite for building a protocol that addresses your actual pathophysiology rather than the average PCOS presentation.

Want this applied to your actual variant profile?

Hormone DNA Report · $79 →